- Pagina principale
- Analisi delle app
- Tempus Provider
- Tempus Provider Vs. Guardant Health Portal
Tempus Provider vs. Guardant Health Portal Utilizzo e statistiche
The Tempus mobile app gives oncology providers fast and reliable access to patient reports, advanced patient search, and real-time order tracking.
View interactive and in-depth patient results with:
- Next-generation sequencing results including genomic variants and immunotherapy markers
- Sortable and filterable clinical decision support tools including treatment implications and clinical trial(s) matched to patient's clinical and molecular profile
- Comprehensive gene descriptions paired with matched therapies
- Quick access to your patient’s structured clinical timeline
- PDF of your full Tempus report all within the app
- Access your patient's data quickly and securely with Touch ID or Face ID
- Instantly know when a new report is available via push notifications
- Check the status of an order from receipt of specimens through sequencing and report delivery
- App Store di Apple
- Gratis
- Settore Medico
Classifica degli store
- -
The Guardant Health iOS app is available for physicians and their staff to conveniently view Guardant Health reports on their iPhones and iPads.
Report Access:
Easily search, sort, and review reports as soon as they are made available.
Simple Sign-in:
Sign-in to your Guardant Health portal account with your username and password.
- App Store di Apple
- Gratis
- Settore Medico
Classifica degli store
- -
Tempus ProviderRanking a confronto con Guardant Health Portal
Confronta la tendenza di classifica Tempus Provider nei ultimi 28 giorni rispetto a Guardant Health Portal
Rank
Nessun dato disponibile
Classifica Tempus Provider vs. Guardant Health Portal per paese a confronto
Confronta la tendenza di classifica Tempus Provider nei ultimi 28 giorni rispetto a Guardant Health Portal
Nessun dato da visualizzare
Fai confronti con qualsiasi sito con la nostra prova gratuita
Tempus Provider VS.
Guardant Health Portal
19icembre d, 2024